by Meriem Bouslouk-Marx | 27 May 2024
Obstacles for patient access to medicines can happen at different stages of a medicine’s life cycle. Therefore, marketing authorisation should not be the ultimate goal. Patient, regulatory and HTA perspectives on an EU approved orphan drug were discussed at the... 
by Meriem Bouslouk-Marx | 6 Oct 2023
The global community of market access professionals met in France on 2 October 2023 at the Market Access Day – the first post-pandemic event of the Market Access Society (MAS). This meeting was also a great opportunity to discuss the latest developments of the benefit... 
by Meriem Bouslouk-Marx | 7 Sep 2023
After Boehringer Ingelheim’s announcement to withdraw a medicine for the treatment of a rare skin disease from the German market on 29 August 2023, a heated debate has erupted on the benefit assessment of new therapies in Germany. Boehringer Ingelheim said the health... 
by Meriem Bouslouk-Marx | 17 Apr 2023
Do you know IMAS? IMAS stands for International Market Access Society. As a matter of fact it derives from MAS, the Market Access Society founded in France more than 10 years ago. The very first meeting of IMAS called ACCESS 2023 Miami Beach took place in April 2023.... 
by Meriem Bouslouk-Marx | 28 Feb 2023
I remember very well the day I asked the G-BA for permission to speak about the specific German benefit assessment of orphan drugs. Although I used to represent the G-BA and AMNOG internationally, I did not dare to give a talk solely on orphan drugs. Why? Because I... 
by Meriem Bouslouk-Marx | 14 Feb 2023
The G-BA took the opportunity to announce its AMNOG work programme for 2023 at a press conference on 14 February 2023. The impartial G-BA Chair professor Josef Hecken highlighted in his introduction speech that the G-BA had made over 1,000 benefit assessment decisions...